<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362812">
  <stage>Registered</stage>
  <submitdate>27/07/2012</submitdate>
  <approvaldate>16/08/2012</approvaldate>
  <actrnumber>ACTRN12612000869875</actrnumber>
  <trial_identification>
    <studytitle>An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (AD)</studytitle>
    <scientifictitle>An Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimers Disease</scientifictitle>
    <utrn />
    <trialacronym>EPOCH</trialacronym>
    <secondaryid>EUCTR2011-003151-20</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>MK-8931 12mg tablets, orally once daily for 78 weeks
MK-8931 40mg tablets, orally once daily for 78 weeks
MK-8931 60mg tablets, orally once daily for 78 weeks
Participants will be randomised to one of these 3 treatments or a matching placebo tablet.</interventions>
    <comparator>matching placebo tablets, identical to MK-8931 but without the active ingredient.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change from Baseline in ADAS-Cog score</outcome>
      <timepoint>78 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>change from Baseline in ADCS-ADL score</outcome>
      <timepoint>78 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>change-from-Baseline in CDR-SB score</outcome>
      <timepoint>78 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change-from-Baseline in total hippocampal
volume using MRI.</outcome>
      <timepoint>78 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change-from-Baseline in Cerebral Spinal Fluid total tau concentration by laboratory analysis</outcome>
      <timepoint>78 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Mild to Moderate Alzheimer's Disease with an MMSE score between 15 and 26. Each subject must have a reliable and competent trial partner/caregiver who has
a close relationship with the subject</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>evidence of vascular dementia or stroke. Other clinically relevant neurological disorder. Clinically relevant or unstable psychiatric disorders. History of hepatitis or liver disease within the previous 6 months. History of malignancy occurring within the previous five years.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer</concealment>
    <sequence>Simple randomisation using a randomisation table created by a computer.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>11/12/2012</anticipatedstartdate>
    <actualstartdate>10/12/2012</actualstartdate>
    <anticipatedenddate>29/01/2016</anticipatedenddate>
    <actualenddate>8/12/2015</actualenddate>
    <samplesize>1960</samplesize>
    <actualsamplesize>2223</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,SA,WA,VIC</recruitmentstate>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Austin Health - Heidelberg Repatriation Hospital - Heidelberg West</hospital>
    <hospital>Hornsby Ku-ring-gai Hospital - Hornsby</hospital>
    <hospital>Hollywood Private Hospital - Nedlands</hospital>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.</primarysponsorname>
    <primarysponsoraddress>One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889-0100, U.S.A.</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.</fundingname>
      <fundingaddress>One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889-0100, U.S.A.</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to test the efficacy and safety of investigational therapy MK-8931 in the treatment of mild to moderate Alzheimer's Disease</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Ethics Committee</ethicname>
      <ethicaddress>Level 3, Hanson Institute
North Terrace
Adelaide 5000
South Australia</ethicaddress>
      <ethicapprovaldate>23/11/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>20/07/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Michael F. Egan, MD</name>
      <address>Merck &amp; Co., Inc.
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889-0100, U.S.A.</address>
      <phone>+1 (267) 305-7678</phone>
      <fax />
      <email>michael.egan@merck.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael F. Egan, MD</name>
      <address>Merck &amp; Co., Inc.
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889-0100, U.S.A.</address>
      <phone>+1 (267) 305-7678</phone>
      <fax />
      <email>michael.egan@merck.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Manisha Moodley</name>
      <address>MSD, Level 1, 26 Talavera Rd, Macquarie Park NSW 2113, Australia</address>
      <phone>+61289888019</phone>
      <fax />
      <email>manisha.moodley@merck.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Michael Woodward</name>
      <address>Heidelberg Repatriation Hospital
145 Studley Road
Heidelberg VIC 3084,</address>
      <phone>+61,3,94962987</phone>
      <fax />
      <email>michael.woodward@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>